A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Healthy
Interventions
DRUG

Midazolam

Treatment A includes a single 2 mg oral dose of midazolam alone. Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.

DRUG

PD-0332991

Treatment B includes 8 daily 125 mg oral doses of PD-0332991.

DRUG

Midazolam

"Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.~Treatment A includes a single 2 mg oral dose of midazolam alone."

DRUG

PD-0332991

Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991.

Trial Locations (1)

33143

Pfizer Investigational Site, South Miami

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01756781 - A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential. | Biotech Hunter | Biotech Hunter